Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
about
Regulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsySynaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and BeyondEpilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken modelLevetiracetam reverses synaptic deficits produced by overexpression of SV2AExploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesisSynaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmissionPuzzling Out Synaptic Vesicle 2 Family Members Functions.Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.MicroRNA regulation of homeostatic synaptic plasticity.Identification of the antiepileptic racetam binding site in the synaptic vesicle protein 2A by molecular dynamics and docking simulations.Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.Kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes correlates with enhanced glutamate release.A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release.Levetiracetam results in increased and decreased alcohol drinking with different access procedures in C57BL/6J miceLevetiracetam: a comprehensive review.Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of ageAre vesicular neurotransmitter transporters potential treatment targets for temporal lobe epilepsy?Synaptic vesicle protein 2A: basic facts and role in synaptic function.The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.SV2A in epilepsy: the plot thickens.Brivaracetam, a Novel Antiepileptic Drug: Is it Effective and Safe? Results from One Phase III Randomized Trial.The Mechanism of Anti-Epileptogenesis by Levetiracetam Treatment is Similar to the Spontaneous Recovery of Idiopathic Generalized Epilepsy during Adolescence.Immunochemical analysis of the expression of SV2C in mouse, macaque and human brain.Kinetic evaluation and test-retest reproducibility of [(11)C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans.Anti-ictogenic and antiepileptogenic properties of brivaracetam in mature and immature rats.Antiepileptic effects of levetiracetam in a rodent neonatal seizure model.Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.Altered balance between excitatory and inhibitory inputs onto CA1 pyramidal neurons from SV2A-deficient but not SV2B-deficient mice.A review of the pharmacology and clinical efficacy of brivaracetam.Expression pattern of synaptic vesicle protein 2 (SV2) isoforms in patients with temporal lobe epilepsy and hippocampal sclerosis.Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.
P2860
Q26859135-2BB7C9C3-7D43-453D-82DB-115F1D414F3BQ28068507-5B7CE908-5170-4AC7-92B8-A5C743C3FEBDQ28477672-8F9E2CC7-47BE-4910-8433-883BA0A33594Q28478633-36D0C905-15A3-4461-9E41-62CD860CF0B5Q28543500-23D3AA17-03A9-432B-9C81-30D8995193A4Q29144205-42BB4392-B286-451F-8880-5D8E4B755368Q33710870-4D544562-B299-447A-8B70-DC0F2DA240AAQ34132754-787DF69B-09EC-4FD7-8C73-83B4C80E4821Q35105269-D78E2BD5-F72D-45F6-A138-28799354D277Q35357221-91C72980-BC23-45CA-866D-6C87CBA14E65Q35761335-5567A8CE-10A6-423B-B8E7-24FFB7F680C0Q36032254-6F3899E2-BC6D-4D90-B8F4-7BC97CCDA1CAQ37092563-9D37FB2C-F0AF-4E6B-9002-3DC8623F2ED3Q37448220-E4CA4114-EDD5-4352-90D2-B80353192C83Q37688063-A399B0BE-EF7A-4E91-B3A5-9174B0650B11Q38086370-D025024C-0484-4F9E-9456-EA01B749AF48Q38134724-2ACD0E8E-50C1-49B3-A8DB-AAE5C66C6F7BQ38150436-5FC158EF-DDC1-4474-B724-9CDD391210F7Q38614499-58AAAAF9-2EC3-47F4-BAF5-4FEEFA0E5550Q38626838-F4680984-D46E-48E3-BC10-0ED3916AD08AQ39164408-5BA6739B-842C-4836-93A1-FD3B0BAA3630Q39553786-A8161DD4-574D-4DAD-A8CE-C5C0415B0543Q41877287-C770E71A-6FFD-41E1-A02B-9E75B71967EAQ47146025-5C83523D-FE57-42AA-BC0C-DC64B8004273Q47258034-725A3E91-F154-4338-9450-AA319F556FA9Q47814823-11077509-3432-4905-B5F1-A24E3C4C75ACQ48258054-1F675908-A481-4686-AC34-FFD31D60FAB9Q48302966-17FAC64E-3CFD-47E4-B4E9-0EDD6784FA1CQ48383809-92640748-031E-4C0B-BF70-B8AB605D2417Q48423402-2FE043E5-DEE7-408C-A278-75472C480737Q49700507-9AC4F921-893B-44D3-A854-C50D2A42CABCQ50747231-8C0815E8-1A94-4A32-854A-2289834F9D01Q51771465-F7BBB53D-8A09-49C7-AAB5-41E758759099Q52147702-1EF31594-48BC-4E84-954C-29D4215AC5A3
P2860
Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Decreased expression of synapt ...... ogenesis and chronic epilepsy.
@en
Decreased expression of synapt ...... ogenesis and chronic epilepsy.
@nl
type
label
Decreased expression of synapt ...... ogenesis and chronic epilepsy.
@en
Decreased expression of synapt ...... ogenesis and chronic epilepsy.
@nl
prefLabel
Decreased expression of synapt ...... ogenesis and chronic epilepsy.
@en
Decreased expression of synapt ...... ogenesis and chronic epilepsy.
@nl
P2093
P1433
P1476
Decreased expression of synapt ...... ogenesis and chronic epilepsy.
@en
P2093
Erwin A van Vliet
Jan A Gorter
Karin Boer
Sandra Redeker
P304
P356
10.1111/J.1528-1167.2008.01727.X
P577
2008-08-19T00:00:00Z